|(R)-5-氨基-2-甲基-N-(1-(萘-1-基)乙基)苯甲酰胺|CsnPharm

CAS No.: 1093070-16-6

GRL0617 is a noncovalent lead inhibitor of Plpro. It inhibited SARS-CoV viral replication in Vero E6 cells with an EC50 of 15μM。

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述The papain-like protease (PLpro) is a viable target for the development of antivirals against coronavirus-caused severe acute respiratory syndrome (SARS-CoV). GRL0617 is a potent competitive inhibitor of PLpro with a K_i value of 0.49 ± 0.08μM. The IC50 value of GRL0617 for PLpro activity in vitro is 0.6 ± 0.1μM. The antiviral EC50 value of GRL0617 against SARS-CoV is 14.5 ± 0.8μM. GRL0617 is unlikely to inhibit other human ubiquitin-specific proteases, such as HAUSP, USP18, UCH-L1, UCH-L3, and papain-like protease (IC50 > 100μM)^[1]. The in vitro IC50 value of GRL0617 against SARS-CoV-2 PLpro is 2.1 ± 0.2μM^[2].
作用机制GRL0617 binds within the S3 and S4 subsites of PLpro. The interaction between them is stabilized through a pair of hydrogen bonds and a series of hydrophobic interactions^[1].
参考文献

实验方案

技术信息

CAS号

1093070-16-6

储存条件

分子式

C20H20N2O

运输

蓝冰

分子量

304.39

别名

溶解度

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

请登录您的专属账户